• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本医院开始治疗的患者催眠药物处方模式:一项使用索赔数据库的全国性、回顾性、纵向观察性研究。

Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database.

作者信息

Inada Ken, Enomoto Minori, Yamato Kentaro, Mishima Kazuo

机构信息

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Department of Medical Technology, School of Health Sciences, Tokyo University of Technology, Tokyo, Japan.

出版信息

Drugs Real World Outcomes. 2021 Sep;8(3):277-288. doi: 10.1007/s40801-021-00244-9. Epub 2021 Mar 13.

DOI:10.1007/s40801-021-00244-9
PMID:33713330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8324698/
Abstract

BACKGROUND

Prolonged treatment of insomnia using benzodiazepine (BZD) receptor agonists, including BZD and non-BZD hypnotic drugs, can cause drug dependence, tolerance, abuse and other adverse events. These side effects are more common and/or severe in older adults taking different hypnotic drugs concomitantly. Therefore, a single prescription is limited to 30 daily doses for most BZD receptor agonists and restrictions apply to the prescription of more than three types of hypnotic drugs in Japan. Little is known, however, about the real-world prescribing pattern of hypnotic drugs in Japan.

OBJECTIVE

We analysed prescribing patterns for hypnotic drugs in Japan to evaluate whether real-world use differs from guideline recommendations.

METHODS

In this nationwide, retrospective, longitudinal, observational study, we analysed the types of hypnotic drugs prescribed, duration of medication and treatment setting in a subset of hospitals in Japan using a hospital-based administrative claims database (Medical Data Vision). Patients initiating treatment with hypnotic drugs between January 2012 and December 2016 were included in the analyses to assess the duration of medication and occurrence of co-prescription of a second and third hypnotic drug, within a year from prescription of the first hypnotic drugs.

RESULTS

In 261,167 patients analysed, the first hypnotic drugs prescribed were BZDs (59.7%), non-BZDs (36.8%), a melatonin receptor agonist [MRA] (3.1%) and an orexin receptor antagonist [ORA] (0.4%). Benzodiazepine and non-BZD hypnotic drugs were mostly prescribed in inpatient settings (57.7% and 63.0%, respectively) and the MRA and ORA mostly in outpatient settings (62.6% and 65.4%, respectively). The departments that prescribed the most patients their first hypnotic drugs were internal medicine (23.6%), general surgery (11.8%), orthopaedic surgery (11.4%) and urology (5.3%). Of the total prescriptions of MRA and ORA as the first hypnotic drugs, 22.0% and 31.8% were in internal medicine, 4.4% each in general surgery, 6.0% and 4.5% in orthopaedic surgery, 9.7% and 4.4% in neurology, and 10.1% and 12.2% in psychiatry departments, respectively. Mean duration of medication was 1.13 months for non-BZDs, 1.15 months for BZDs, 1.29 months for the ORA and 1.83 months for the MRA. Overall, 5.3% (95% confidence interval 5.2-5.4) of patients were prescribed a second hypnotic drug; of these, 8.4% (95% confidence interval 8.0-8.9) were prescribed at least three hypnotic drugs within a year. Patients who were prescribed three or more hypnotic drugs received higher doses of the first drug than patients who received fewer hypnotic drugs.

CONCLUSIONS

Benzodiazepine receptor agonists were the most common hypnotic drugs prescribed as the first drug to patients in Japan. Further education and awareness may be needed on the risk of complications and adverse events associated with these therapies. The duration of BZD receptor agonist use was shorter than for the MRA and ORA, in accordance with prescribing guidelines. Long-term use and co-prescribing of hypnotic drugs were also uncommon.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/97090c2887b5/40801_2021_244_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/66a48fbe91f9/40801_2021_244_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/7cc8148a79f3/40801_2021_244_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/97090c2887b5/40801_2021_244_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/66a48fbe91f9/40801_2021_244_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/7cc8148a79f3/40801_2021_244_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1ed/8324698/97090c2887b5/40801_2021_244_Fig3_HTML.jpg
摘要

背景

使用苯二氮䓬(BZD)受体激动剂(包括BZD和非BZD催眠药物)长期治疗失眠可导致药物依赖、耐受性、滥用及其他不良事件。这些副作用在同时服用不同催眠药物的老年人中更为常见和/或严重。因此,在日本,大多数BZD受体激动剂的单次处方限量为每日30剂,且限制开具超过三种类型的催眠药物。然而,对于日本催眠药物的实际处方模式知之甚少。

目的

我们分析了日本催眠药物的处方模式,以评估实际使用情况是否与指南建议不同。

方法

在这项全国性、回顾性、纵向观察性研究中,我们使用基于医院的行政索赔数据库(Medical Data Vision)分析了日本部分医院开具的催眠药物类型、用药时长及治疗环境。纳入2012年1月至2016年12月开始使用催眠药物治疗的患者,以评估用药时长以及在开具第一种催眠药物后的一年内联合开具第二种和第三种催眠药物的情况。

结果

在分析的261,167例患者中,首次开具的催眠药物为BZD类(59.7%)、非BZD类(36.8%)、褪黑素受体激动剂[MRA](3.1%)和食欲素受体拮抗剂[ORA](0.4%)。BZD和非BZD催眠药物大多在住院环境中开具(分别为57.7%和63.0%),而MRA和ORA大多在门诊环境中开具(分别为62.6%和65.4%)。为最多患者开具第一种催眠药物的科室是内科(23.6%)、普通外科(11.8%)、骨科(11.4%)和泌尿外科(5.3%)。作为第一种催眠药物的MRA和ORA的总处方中,分别有22.0%和31.8%在内科开具,普通外科各占4.4%,骨科分别为6.0%和4.5%,神经科分别为9.7%和4.4%,精神科分别为10.1%和12.2%。非BZD类药物的平均用药时长为1.13个月,BZD类为1.15个月,ORA为1.29个月,MRA为1.83个月。总体而言,5.3%(95%置信区间5.2 - 5.4)的患者开具了第二种催眠药物;其中,8.4%(95%置信区间8.0 - 8.9)的患者在一年内开具了至少三种催眠药物。开具三种或更多催眠药物的患者比开具较少催眠药物的患者接受的第一种药物剂量更高。

结论

在日本,BZD受体激动剂是最常作为第一种药物开具给患者的催眠药物。可能需要进一步开展教育并提高对这些治疗相关并发症和不良事件风险的认识。根据处方指南,BZD受体激动剂的使用时长比MRA和ORA短。催眠药物的长期使用和联合开具也不常见。

相似文献

1
Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database.日本医院开始治疗的患者催眠药物处方模式:一项使用索赔数据库的全国性、回顾性、纵向观察性研究。
Drugs Real World Outcomes. 2021 Sep;8(3):277-288. doi: 10.1007/s40801-021-00244-9. Epub 2021 Mar 13.
2
Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database.日本催眠处方治疗失眠的趋势和模式:一项全国性日本索赔数据库分析。
BMC Psychiatry. 2023 Apr 20;23(1):278. doi: 10.1186/s12888-023-04683-2.
3
Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.2006 年至 2013 年期间儿童、青少年和年轻成人的苯二氮䓬类药物处方:一项全人群登记-链接研究。
PLoS Med. 2018 Aug 7;15(8):e1002635. doi: 10.1371/journal.pmed.1002635. eCollection 2018 Aug.
4
Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database.催眠药物治疗残余失眠和复发性重度抑郁障碍的模式:使用日本健康保险索赔数据库的回顾性队列研究。
BMC Psychiatry. 2021 Jan 13;21(1):40. doi: 10.1186/s12888-021-03046-z.
5
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.教育对精神分裂症和重度抑郁症治疗指南的影响以及对精神科医生催眠药物处方行为的影响:一项多中心研究。
BMC Psychiatry. 2024 May 29;24(1):399. doi: 10.1186/s12888-024-05816-x.
6
Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database.日本失眠患者中食欲素受体拮抗剂处方的相关因素:基于日本全国索赔数据库的分析
Drugs Real World Outcomes. 2023 Jun;10(2):271-281. doi: 10.1007/s40801-023-00356-4. Epub 2023 Mar 3.
7
A retrospective review on benzodiazepine use: A case study from a chronic dispensary unit.苯二氮䓬类药物使用情况的回顾性研究:来自一家慢性病药房的案例分析
S Afr Med J. 2019 Jan 31;109(2):127-132. doi: 10.7196/SAMJ.2019.v109i2.13347.
8
The use of benzodiazepine monotherapy for major depression before and after implementation of guidelines for benzodiazepine use.苯二氮䓬类药物单药治疗在苯二氮䓬类药物使用指南实施前后对重度抑郁症的作用。
J Clin Pharm Ther. 2011 Oct;36(5):577-84. doi: 10.1111/j.1365-2710.2010.01213.x. Epub 2010 Nov 10.
9
Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics.日本政策和新型催眠药对催眠药长期处方的影响。
Psychiatry Clin Neurosci. 2023 May;77(5):264-272. doi: 10.1111/pcn.13525. Epub 2023 Jan 26.
10
Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan.与长期开具苯二氮䓬类药物处方相关的因素:使用日本医疗保险数据库的回顾性队列研究。
BMJ Open. 2019 Jul 26;9(7):e029641. doi: 10.1136/bmjopen-2019-029641.

引用本文的文献

1
A Cross-Sectional Study on the Drug Use of Insomnia in a Chinese Medicine Hospital in Shenzhen.深圳某中医院失眠症用药情况的横断面研究
Psychiatry Clin Psychopharmacol. 2025 Jul 28;35(3):295-303. doi: 10.5152/pcp.2025.24923.
2
Evaluation of the effects of a team-based systematic prevention and management program for postoperative orthopedic older patients: A retrospective cohort study.基于团队的骨科老年患者术后系统预防与管理项目效果评估:一项回顾性队列研究。
PCN Rep. 2024 Oct 9;3(4):e70021. doi: 10.1002/pcn5.70021. eCollection 2024 Dec.
3
Prescribing Cascades of Loop Diuretics and Anti-vertigo Drugs Following Treatment with Gabapentinoids and Benzodiazepines: Prescription Sequence Symmetry Analysis of a Large-Scale Claims Database Including Japanese Older Adults.

本文引用的文献

1
Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data.瑞士养老院的药物处方模式、多种药物治疗和潜在不适当药物:基于索赔数据的描述性分析。
Swiss Med Wkly. 2019 Sep 30;149:w20126. doi: 10.4414/smw.2019.20126. eCollection 2019 Sep 23.
2
French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol.法国国家健康保险数据库分析和现场研究,重点关注安全处方笺对佐匹克隆消费和镇静药物滥用的影响:ZORRO 研究方案。
BMJ Open. 2019 Jun 28;9(6):e027443. doi: 10.1136/bmjopen-2018-027443.
3
加巴喷丁类药物和苯二氮䓬类药物治疗后袢利尿剂和抗眩晕药物的处方级联:对包括日本老年人在内的大规模索赔数据库的处方序列对称性分析
Drugs Real World Outcomes. 2024 Sep;11(3):529-540. doi: 10.1007/s40801-024-00446-x. Epub 2024 Aug 8.
4
Digital cognitive-behavioural therapy application compared with zolpidem for the treatment of insomnia: protocol for an exploratory randomised controlled trial.数字认知行为疗法应用与唑吡坦治疗失眠的比较:一项探索性随机对照试验方案。
BMJ Open. 2024 Jun 25;14(6):e081205. doi: 10.1136/bmjopen-2023-081205.
5
Low-dose benzodiazepine receptor agonists may be completely replaced by lemborexant at about the same dose.低剂量苯二氮䓬受体激动剂可能会在大约相同剂量下被伦扎必利完全替代。
PCN Rep. 2022 Aug 9;1(3):e32. doi: 10.1002/pcn5.32. eCollection 2022 Sep.
6
Hypnotic prescriptions in Japan may be shifting from benzodiazepine receptor agonists to other types of hypnotics, melatonin receptor agonists, and orexin receptor antagonists.在日本,催眠药物的处方可能正从苯二氮䓬受体激动剂转向其他类型的催眠药、褪黑素受体激动剂和食欲素受体拮抗剂。
PCN Rep. 2023 Jun 19;2(2):e113. doi: 10.1002/pcn5.113. eCollection 2023 Jun.
7
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo Tablets.仑美曲索治疗失眠患者的安全性和疗效:达维吉奥片上市后观察性研究结果。
Drugs R D. 2024 Jun;24(2):211-226. doi: 10.1007/s40268-024-00462-w. Epub 2024 Jun 6.
8
Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.日本指南推荐的催眠药物治疗失败和长期处方风险。
JAMA Netw Open. 2024 Apr 1;7(4):e246865. doi: 10.1001/jamanetworkopen.2024.6865.
9
A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists.一项回顾性临床实践研究,比较双食欲素受体拮抗剂和褪黑素受体激动剂在从长期苯二氮䓬受体激动剂转换的患者中的效用。
J Clin Sleep Med. 2024 Apr 1;20(4):603-613. doi: 10.5664/jcsm.10946.
10
Descriptive Study of Patients Treated in a Psychosomatic Internal Medicine Declared by Japanese Family Medicine Clinic.日本家庭医学诊所申报的身心内科治疗患者的描述性研究。
J Clin Med Res. 2023 Jul;15(7):360-367. doi: 10.14740/jocmr4939. Epub 2023 Jul 31.
Trends in prescriptions for sedative-hypnotics among Korean adults: a nationwide prescription database study for 2011-2015.
韩国成年人镇静催眠药物处方趋势:2011-2015 年全国处方数据库研究。
Soc Psychiatry Psychiatr Epidemiol. 2019 Apr;54(4):477-484. doi: 10.1007/s00127-018-1615-x. Epub 2018 Nov 7.
4
Pharmacotherapy of Insomnia.失眠的药物治疗
J Cent Nerv Syst Dis. 2018 Apr 19;10:1179573518770672. doi: 10.1177/1179573518770672. eCollection 2018.
5
A systematic review of regulatory and educational interventions to reduce the burden associated with the prescriptions of sedative-hypnotics in adults treated for sleep disorders.一项关于监管和教育干预措施的系统评价,这些措施旨在减轻接受睡眠障碍治疗的成年人中与镇静催眠药处方相关的负担。
PLoS One. 2018 Jan 22;13(1):e0191211. doi: 10.1371/journal.pone.0191211. eCollection 2018.
6
What can predict and prevent the long-term use of benzodiazepines?哪些因素可预测和预防苯二氮䓬类药物的长期使用?
J Psychiatr Res. 2018 Feb;97:94-100. doi: 10.1016/j.jpsychires.2017.11.012. Epub 2017 Nov 24.
7
European guideline for the diagnosis and treatment of insomnia.欧洲失眠症诊断与治疗指南。
J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5.
8
Long-term use of benzodiazepines in older patients in Germany: a retrospective analysis.德国老年患者长期使用苯二氮䓬类药物:一项回顾性分析。
Ther Adv Psychopharmacol. 2017 Jul;7(6-7):191-200. doi: 10.1177/2045125317696454. Epub 2017 Mar 1.
9
Long-term benzodiazepine and Z-drugs use in England: a survey of general practice [corrected].英国长期使用苯二氮䓬类药物和 Z 类药物:全科医学调查 [更正]。
Br J Gen Pract. 2017 Sep;67(662):e609-e613. doi: 10.3399/bjgp17X691865. Epub 2017 Jul 17.
10
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.患者与医生对助眠药物安全性信息的认知:一项定性研究
Drug Saf. 2017 Jun;40(6):531-542. doi: 10.1007/s40264-017-0516-3.